drugset / Trial / NCT06804824
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
A FIH study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of VVD-159642, a rat sarcoma viral oncogene-phosphatidylinositol 3-kinase alpha (RAS-PI3Kα) inhibitor, as a single agent and in combination with either sotorasib or trametinib in participants with advanced solid tumors.
Timeline
- Start
- 2025-02-25
- Primary completion
- 2027-08-01
- Completion
- 2027-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sotorasib | Small molecule | — | Oral |
| Subject | Trametinib | Small molecule | — | Oral |
| Subject | VVD-159642 | Unknown | — | Oral |